PEPTIDEREPORT

Video claim watch

Doctors explain how Wegovy and Ozempic work | 60 Minutes

Mainstream 60 Minutes coverage providing clinical and regulatory context for Wegovy/Ozempic.

60 Minutes channel10:00 runtime647K views when checked

Published Jan 1, 2023. Metadata checked Jul 1, 2026.

Watch on YouTube

Transcript review

5 material claims logged

Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags2 source gaps

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

clear mainstream explanation but it minimizes variability in adverse effects.

auto-caption available; no chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:00:05
Mechanism

says obesity is a disease of energy-balance regulatory pathways, not simply personal control.

Review topic: obesity framing.

Checked against: Primary-source record still needed

Primary-source mapping pending.

00:01:45
High-risk safety claim

characterizes pancreatitis as very rare and GI effects as generally manageable/transient.

Review topic: safety.

Checked against: Wegovy prescribing information

avoid universal “goes away” language.

Timestamp unavailable
Safety context

The segment includes product-use/dose-escalation detail.

Review topic: approved prescribing.

Checked against: Primary-source record still needed

label; Peptide Report should link to prescribing information rather than restate instructions.

Connected research

Compounds discussed

Semaglutide Semaglutide is a GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus for specific FDA-approved indications. Randomized trials support diabetes and chronic weight-management uses. Off-label, compounded, and broader behavioral claims require separate evidence and regulatory review.

Source check

Records used in this claim audit